Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 6/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | HTR6 | P50406 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MET | P08581 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30900326 | 0.76 | SIRT6 (0.67) | SIRT6MAPTHTR6ALDH1A1MAPK1 | |
| SCHEMBL1527190 | 0.76 | SIRT6 (0.67) | SIRT6MAPTHTR6ALDH1A1MAPK1 | |
| SCHEMBL30532598 | 0.75 | SIRT6 (0.75) | SIRT6MAPTHTR6ALDH1A1MAPK1 | |
| SCHEMBL27997682 | 0.75 | SIRT6 (0.75) | SIRT6MAPTHTR6ALDH1A1MAPK1 | |
| SCHEMBL12362451 | 0.75 | HTR1A (0.45) | ALDH1A1CYP1A2CYP2D6SMN1; SMN2 | |
| SCHEMBL14938605 | 0.73 | MAPT (0.72) | SIRT6MAPTHTR6ALDH1A1LMNA | |
| SCHEMBL1981534 | 0.73 | ALDH1A1 (0.74) | SIRT6MAPTHTR6ALDH1A1MAPK1 | |
| SCHEMBL24073869 | 0.73 | SIRT6 (0.60) | SIRT6MAPTHTR6ALDH1A1MET | |
| SCHEMBL27306274 | 0.73 | HTR3A (0.50) | MAPTMETMAPK1HTR3ASMN1; SMN2 | |
| SCHEMBL30912575 | 0.73 | SIRT6 (0.59) | SIRT6MAPTHTR6ALDH1A1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373657-B1 | 5,7-DIHYDRO-6H-PYRIMIDO[5,4-D][1]BENZAZEPIN-6-THIONES AS PLK INHIBITORS | MILLENNIUM PHARM INC (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2373657-B1 | 5,7-DIHYDRO-6H-PYRIMIDO[5,4-D][1]BENZAZEPIN-6-THIONES AS PLK INHIBITORS | MILLENNIUM PHARM INC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20150175542-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175542-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175542-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20140194410-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194410-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194410-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8507667-B2 | Thiolactams and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507667-B2 | Thiolactams and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20110257157-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| EP-2373657-A1 | 5, 7-DIHYDRO- 6H-PYRIMIDO Ý 5, 4-D¨Ý 1¨BENZAZEPIN-6-THIONES AS PLK INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-7998952-B2 | Thiolactams and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998952-B2 | Thiolactams and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998952-B2 | Thiolactams and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100179126-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100179126-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100179126-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| WO-2010065134-A1 | 5, 7-DIHYDRO- 6H-PYRIMIDO [ 5, 4-D] [ 1 ] BENZAZEPIN-6-THIONES AS PLK INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065134-A1 | 5, 7-DIHYDRO- 6H-PYRIMIDO [ 5, 4-D] [ 1 ] BENZAZEPIN-6-THIONES AS PLK INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179126-A1 | THIOLACTAMS AND USES THEREOF | PLK3, PLK4, PLK2 | SIRT6 1183/4885MAPT 4076/4885HTR6 921/4885 |
| US-20110257157-A1 | THIOLACTAMS AND USES THEREOF | PLK3, PLK4, PLK2 | SIRT6 1183/4885MAPT 4076/4885HTR6 921/4885 |
| US-20150175542-A1 | THIOLACTAMS AND USES THEREOF | PLK3, PLK4, PLK2 | SIRT6 1183/4885MAPT 4076/4885HTR6 921/4885 |
| US-20140194410-A1 | THIOLACTAMS AND USES THEREOF | PLK3, PLK4, PLK2 | SIRT6 1183/4885MAPT 4076/4885HTR6 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.